Pembrolizumab slows MSI-H-dMMR metastatic CRC
(HealthDay)—For the first-line treatment of microsatellite-instability-high (MSI-H) or mismatch-repair-deficient (dMMR) metastatic colorectal cancer, pembrolizumab is superior to chemotherapy for prolonging progression-free ...
Dec 3, 2020
0
0